Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

IPSEN – Buy-back programme – Art 5 of MAR – Week 49- 2025

Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

IPSEN – Buy-back programme – Art 5 of MAR – Week 48 – 2025

IPSEN – Buy-back programme – Art 5 of MAR – Week 47 – 2025

IPSEN – Buy-back programme – Art 5 of MAR – Week 46 – 2025

IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2025

Ipsen – October 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2025